Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.77 |
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851236 | 1.00 | GBA1 (0.79) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL2470122 | 0.89 | GBA1 (1.00) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL3853060 | 0.87 | ALDH1A1 (1.00) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL8484438 | 0.86 | GBA1 (0.70) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL6584417 | 0.85 | HDAC3 (0.78) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL8208140 | 0.85 | HDAC3 (0.78) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL5028416 | 0.84 | KMT2A (0.70) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL5028418 | 0.84 | KMT2A (0.70) | GBA1KMT2AALDH1A1MEN1CYP2C9 | |
| SCHEMBL8394068 | 0.82 | GBA1 (0.86) | GBA1KMT2AALDH1A1MEN1POLB | |
| SCHEMBL3811045 | 0.82 | GBA1 (0.86) | GBA1KMT2AALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1306085-B1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7034034-B2 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-6987188-B2 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT | 2006-01-17 | — | — | US | disclosed |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | DAX SCOTT (US) | 2005-03-10 | — | — | US | disclosed |
| US-6841552-B1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1076644-B1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NEUROGEN CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1306085-A1 | 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor | Neurogen Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1177172-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1076644-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-2000068197-A1 | 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6140354-A | FOR TREATMENT OF DISORDERS OR DISEASE STATES CAUSED BY EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, HYPERTENSION, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1999055667-A1 | N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144290-A1 | Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives | NPY5R, NPY4R, NPY1R | GBA1 3318/4885KMT2A 2283/4885ALDH1A1 4260/4885 |
| US-20050054709-A1 | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptideYreceptors ligands useful in the treatment of obesity and other disorders | NPY1R, NPY4R, NPY2R | GBA1 2790/4885KMT2A 3064/4885ALDH1A1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.